These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 20428780)

  • 1. Inhibition of MSP-RON signaling pathway in cancer cells by a novel soluble form of RON comprising the entire sema sequence.
    Ma Q; Zhang K; Yao HP; Zhou YQ; Padhye S; Wang MH
    Int J Oncol; 2010 Jun; 36(6):1551-61. PubMed ID: 20428780
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Crystal structure of the Sema-PSI extracellular domain of human RON receptor tyrosine kinase.
    Chao KL; Tsai IW; Chen C; Herzberg O
    PLoS One; 2012; 7(7):e41912. PubMed ID: 22848655
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Deletion or insertion in the first immunoglobulin-plexin-transcription (IPT) domain differentially regulates expression and tumorigenic activities of RON receptor Tyrosine Kinase.
    Ma Q; Zhang K; Guin S; Zhou YQ; Wang MH
    Mol Cancer; 2010 Nov; 9():307. PubMed ID: 21114864
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The soluble sema domain of the RON receptor inhibits macrophage-stimulating protein-induced receptor activation.
    Angeloni D; Danilkovitch-Miagkova A; Miagkov A; Leonard EJ; Lerman MI
    J Biol Chem; 2004 Jan; 279(5):3726-32. PubMed ID: 14597639
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structural basis for the binding specificity of human Recepteur d'Origine Nantais (RON) receptor tyrosine kinase to macrophage-stimulating protein.
    Chao KL; Gorlatova NV; Eisenstein E; Herzberg O
    J Biol Chem; 2014 Oct; 289(43):29948-60. PubMed ID: 25193665
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ribosomal protein S6 kinase (RSK)-2 as a central effector molecule in RON receptor tyrosine kinase mediated epithelial to mesenchymal transition induced by macrophage-stimulating protein.
    Ma Q; Guin S; Padhye SS; Zhou YQ; Zhang RW; Wang MH
    Mol Cancer; 2011 May; 10():66. PubMed ID: 21619683
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Blocking tumorigenic activities of colorectal cancer cells by a splicing RON receptor variant defective in the tyrosine kinase domain.
    Wang MH; Lao WF; Wang D; Luo YL; Yao HP
    Cancer Biol Ther; 2007 Jul; 6(7):1121-9. PubMed ID: 17611409
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative characterization of the HGF/Met and MSP/Ron systems in primary pancreatic adenocarcinoma.
    Vanderwerff BR; Church KJ; Kawas LH; Harding JW
    Cytokine; 2019 Nov; 123():154762. PubMed ID: 31254927
    [TBL] [Abstract][Full Text] [Related]  

  • 9. STK/RON receptor tyrosine kinase mediates both apoptotic and growth signals via the multifunctional docking site conserved among the HGF receptor family.
    Iwama A; Yamaguchi N; Suda T
    EMBO J; 1996 Nov; 15(21):5866-75. PubMed ID: 8918464
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic implications of a human neutralizing antibody to the macrophage-stimulating protein receptor tyrosine kinase (RON), a c-MET family member.
    O'Toole JM; Rabenau KE; Burns K; Lu D; Mangalampalli V; Balderes P; Covino N; Bassi R; Prewett M; Gottfredsen KJ; Thobe MN; Cheng Y; Li Y; Hicklin DJ; Zhu Z; Waltz SE; Hayman MJ; Ludwig DL; Pereira DS
    Cancer Res; 2006 Sep; 66(18):9162-70. PubMed ID: 16982759
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Macrophage stimulating protein (MSP) binds to its receptor via the MSP beta chain.
    Wang MH; Julian FM; Breathnach R; Godowski PJ; Takehara T; Yoshikawa W; Hagiya M; Leonard EJ
    J Biol Chem; 1997 Jul; 272(27):16999-7004. PubMed ID: 9202013
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tyrosine kinase receptor RON and its ligand MSP in Merkel cell carcinoma.
    Nagahama J; Daa T; Yada N; Kashima K; Fujiwara S; Saikawa T; Yokoyama S
    Pathol Res Pract; 2011 Aug; 207(8):463-7. PubMed ID: 21723047
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of the ron gene product as the receptor for the human macrophage stimulating protein.
    Wang MH; Ronsin C; Gesnel MC; Coupey L; Skeel A; Leonard EJ; Breathnach R
    Science; 1994 Oct; 266(5182):117-9. PubMed ID: 7939629
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Point mutations and overexpression of Ron induce transformation, tumor formation, and metastasis.
    Peace BE; Hughes MJ; Degen SJ; Waltz SE
    Oncogene; 2001 Sep; 20(43):6142-51. PubMed ID: 11593422
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of TLR4-induced IκB kinase activity by the RON receptor tyrosine kinase and its ligand, macrophage-stimulating protein.
    Ray M; Yu S; Sharda DR; Wilson CB; Liu Q; Kaushal N; Prabhu KS; Hankey PA
    J Immunol; 2010 Dec; 185(12):7309-16. PubMed ID: 21078906
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Requirement of phosphatidylinositol-3 kinase for epithelial cell migration activated by human macrophage stimulating protein.
    Wang MH; Montero-Julian FA; Dauny I; Leonard EJ
    Oncogene; 1996 Nov; 13(10):2167-75. PubMed ID: 8950984
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The RON receptor tyrosine kinase promotes MSP-independent cell spreading and survival in breast epithelial cells.
    Feres KJ; Ischenko I; Hayman MJ
    Oncogene; 2009 Jan; 28(2):279-88. PubMed ID: 18836480
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The macrophage stimulating protein/Ron pathway as a potential therapeutic target to impede multiple mechanisms involved in breast cancer progression.
    Kretschmann KL; Eyob H; Buys SS; Welm AL
    Curr Drug Targets; 2010 Sep; 11(9):1157-68. PubMed ID: 20545605
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Significance of the entire C-terminus in biological activities mediated by the RON receptor tyrosine kinase and its oncogenic variant RON160.
    Lu Y; Yao HP; Wang MH
    J Exp Clin Cancer Res; 2008 Oct; 27(1):55. PubMed ID: 18950514
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The MSP-RON axis stimulates cancer cell growth in models of triple negative breast cancer.
    Millar R; Kilbey A; Remak SJ; Severson TM; Dhayade S; Sandilands E; Foster K; Bryant DM; Blyth K; Coffelt SB
    Mol Oncol; 2020 Aug; 14(8):1868-1880. PubMed ID: 32484599
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.